share_log

宜明昂科-B:自願公告 – IMM01(替達派西普)聯合阿扎胞苷獲國家藥監局批准進行CMML一線治療的III期臨床試驗

IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE FOR THE FIRST-LINE TREATMENT OF CMML

Hong Kong Stock Exchange ·  Jun 2 19:20
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more